Correlation Engine 2.0
Clear Search sequence regions

  • abelson (1)
  • ABL 1 (1)
  • aorta (1)
  • CD31 (2)
  • endothelium (1)
  • nitric oxide (4)
  • patients (3)
  • receptor (1)
  • signal (1)
  • Src (1)
  • VE cadherin (2)
  • VE- PTP (16)
  • VEGFR2 (2)
  • Sizes of these terms reflect their relevance to your search.

    Receptor-type vascular endothelial protein tyrosine phosphatase (VE-PTP) dephosphorylates Tie-2 as well as CD31, VE-cadherin and VEGFR2. The latter form a signal transduction complex that mediates the endothelial cell response to shear stress, including the activation of the endothelial nitric oxide (NO) synthase (eNOS). As VE-PTP expression is increased in diabetes, we investigated the consequences of VE-PTP inhibition (using AKB-9778) on blood pressure in diabetic patients and the role of VE-PTP in the regulation of eNOS activity and vascular reactivity. In diabetic patients AKB-9778 significantly lowered systolic and diastolic blood pressure. This could be linked to elevated NO production, as AKB increased NO generation by cultured endothelial cells and elicited the NOS inhibitor-sensitive relaxation of endothelium-intact rings of mouse aorta. At the molecular level, VE-PTP inhibition increased the phosphorylation of eNOS on Tyr81 and Ser1177 (human sequence). The PIEZO1 activator Yoda1, which was used to mimic the response to shear stress, also increased eNOS Tyr81 phosphorylation, an effect that was enhanced by VE-PTP inhibition. Two kinases i.e. abelson-tyrosine protein kinase (ABL)1 and Src were identified as eNOS Tyr81 kinases as their inhibition and downregulation significantly reduced the basal and Yoda1-induced tyrosine phosphorylation and activity of eNOS. VE-PTP, on the other hand, formed a complex with eNOS in endothelial cells and directly dephosphorylated eNOS Tyr81 in vitro. Finally, phosphorylation of eNOS on Tyr80 (murine sequence) was found to be reduced in diabetic mice and diabetes-induced endothelial dysfunction (isolated aortic rings) was blunted by VE-PTP inhibition. VE-PTP inhibition enhances eNOS activity to improve endothelial function and decrease blood pressure indirectly, through the activation of Tie-2 and the CD31/VE-cadherin/VEGFR2 complex, and directly by dephosphorylating eNOS Tyr81. VE-PTP inhibition, therefore, represents an attractive novel therapeutic option for diabetes-induced endothelial dysfunction and hypertension. Diabetes and hypertension are associated with endothelial dysfunction, therefore, strategies that increase NO bioavailability are likely to be beneficial. In this study, VE-PTP inhibition using AKB-9778 lowered systolic and diastolic blood pressure in diabetic patients. Mechanistically, VE-PTP inhibition improved endothelial function by activating different signaling pathways that converged to increase eNOS activity. VE-PTP expression was increased in diabetic mice and the VE-PTP inhibitor abrogated diabetes-induced endothelial dysfunction. Thus, this study highlights the clinical feasibility of VE-PTP inhibition to improve endothelial dysfunction and treat hypertension. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions please email:


    Mauro Siragusa, Alberto Fernando Oliveira Justo, Pedro Felipe Malacarne, Anna Strano, Akshay Buch, Barbara Withers, Kevin G Peters, Ingrid Fleming. VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes. Cardiovascular research. 2020 Jul 11

    PMID: 32653904

    View Full Text